$140 Million is the total value of Aisling Capital Management LP's 19 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 9.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $55,099,000 | -10.5% | 6,068,125 | 0.0% | 39.31% | +18.3% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $19,721,000 | +10.7% | 1,025,000 | 0.0% | 14.07% | +46.3% | |
| GLUE | Monte Rosa Therapeutics Inc. (GLUE) | $14,237,000 | -31.0% | 1,472,331 | 0.0% | 10.16% | -8.8% | |
| BMEA | Biomea Fusion Inc. (BMEA) | $9,569,000 | +168.6% | 798,757 | 0.0% | 6.83% | +255.2% | |
| ACRS | Aclaris Theraputics Inc. (ACRS) | $8,857,000 | -19.0% | 634,455 | 0.0% | 6.32% | +7.0% | |
| NUVB | Nuvation Bio Inc. (NUVB) | $8,233,000 | -38.4% | 2,541,009 | 0.0% | 5.87% | -18.6% | |
| VRNA | Verona Pharma plc (VRNA)sponsored ads | $5,583,000 | -16.0% | 1,332,485 | 0.0% | 3.98% | +11.0% | |
| ELEV | Elevation Oncology Inc. (ELEV) | $3,969,000 | -44.4% | 2,834,910 | 0.0% | 2.83% | -26.5% | |
| TALS | Talaris Therapeutics Inc. (TALS) | $3,080,000 | -54.2% | 682,923 | 0.0% | 2.20% | -39.4% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $2,692,000 | -42.4% | 1,043,267 | 0.0% | 1.92% | -23.8% | |
| RPHM | Reneo Pharmaceuticals Inc. (RPHM) | $2,348,000 | -9.9% | 886,075 | 0.0% | 1.68% | +19.1% | |
| SPRB | Spruce Biosciences, Inc. (SPRB) | $2,098,000 | -13.4% | 1,205,511 | 0.0% | 1.50% | +14.4% | |
| VIRX | Viracta Therapeutics Inc. (VIRX) | $1,120,000 | -18.5% | 288,571 | 0.0% | 0.80% | +7.8% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $1,037,000 | -25.0% | 3,142,857 | 0.0% | 0.74% | -0.8% | |
| AVRO | AVROBIO, Inc. (AVRO) | $929,000 | -30.3% | 1,009,779 | 0.0% | 0.66% | -7.8% | |
| AGLE | Aeglea Biotherapeutics Inc. (AGLE) | $854,000 | -78.0% | 1,691,151 | 0.0% | 0.61% | -71.0% | |
| BCEL | Atreca Inc. (BCEL) | $694,000 | -43.5% | 387,653 | 0.0% | 0.50% | -25.3% | |
| ZSAN | Sell | Zosano Pharma Corporation (ZSAN) | $24,000 | -96.1% | 77,663 | -97.1% | 0.02% | -94.8% |
| Sell | Nabriva Therapeutics plc (NBRV) | $16,000 | -80.0% | 90,000 | -52.9% | 0.01% | -74.4% | |
| OBSV | Exit | ObsEva SA (OBSV) | $0 | – | -394,838 | -100.0% | -0.32% | – |
| HRMY | Exit | Harmony Biosciences Holdings Inc. (HRMY) | $0 | – | -342,815 | -100.0% | -9.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.